Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

Psoriasis is a common inflammatory skin disease with multiple comorbidities, including psoriatic arthritis and coronary artery disease, that can severely impact an individual’s quality of life and daily functioning. In recent years, enhanced understanding of the pathogenesis of psoriasis, especially...

Full description

Saved in:
Bibliographic Details
Published in:American journal of clinical dermatology 2021-03, Vol.22 (2), p.173-192
Main Authors: Yang, Kevin, Oak, Allen S. W., Elewski, Boni E.
Format: Article
Language:English
Subjects:
Arthritis
Cardiovascular disease
Cytokines
Dendritic cells
Dermatology
Drug dosages
Erythema
FDA approval
Immune system
Infections
Medicine
Medicine & Public Health
Monoclonal antibodies
Pathogenesis
Patients
Pharmaceutical industry
Pharmacology/Toxicology
Pharmacotherapy
Psoriasis
Psoriatic arthritis
Quality of life
Review
Review Article
Skin
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Psoriasis is a common inflammatory skin disease with multiple comorbidities, including psoriatic arthritis and coronary artery disease, that can severely impact an individual’s quality of life and daily functioning. In recent years, enhanced understanding of the pathogenesis of psoriasis, especially the role of T helper 17 cells, has resulted in the development of new classes of biologic drugs targeting modulators along its disease pathway. Among these, inhibitors of interleukin-23 (e.g., ustekinumab, guselkumab, tildrakizumab, and risankizumab) have emerged as safe and effective options for the treatment of moderate-to-severe plaque psoriasis; ustekinumab and guselkumab have additionally been approved to treat psoriatic arthritis. Selective interleukin-23 inhibitors require less frequent dosing than interleukin-17 inhibitors and may possess a more favorable risk profile without an increased risk of candidiasis or inflammatory bowel disease. Overall, these highly effective medications are contributing to a rising standard for psoriasis outcomes through resolution of skin lesions and joint manifestations and improvement of patient quality of life.
ISSN:1175-0561
1179-1888
DOI:10.1007/s40257-020-00578-0